A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria

Background The survival of patients with advanced hepatocellular carcinoma (HCC) is highly variable due to heterogeneous tumoral characteristics. We proposed and validated an albumin–bilirubin (ALBI)-based model for HCC beyond Milan criteria, the ALBI-HOME, for these patients.